Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 54-week, Multi-centre, 2-arm, Randomised Controlled Trial to Assess Home Monitoring for Lung Function and Patient Reported Outcome Measurements Vs. Usual Care in RheuMatic Disease-associated Interstitial Lung Disease: the RMD-mILDer Trial

NCT06732674 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT06732674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06732674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 54-week, Multi-centre, 2-arm, Randomised Controlled Trial to Assess Home Monitoring for Lung Function and Patient Reported Outcome Measurements Vs. Usual Care in RheuMatic Disease-associated Interstitial Lung Disease: the RMD-mILDer Trial
Lead sponsor
Oslo University Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
December 16, 2024
Completion date
February 28, 2028
Enrollment
218 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

connective tissue diseases, dermatomyositis, interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere, rheumatoid arthritis, sjogren syndrome with lung involvement, systemic sclerosis pulmonary